Screener / SEC EDGAR /CIK 0001109354 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Technology peers:
Nasdaq Technology · Lab Instruments

Bruker Corp BRKR

We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. 10-K, Item 1

Employees
11,085
Headquarters
Billerica, MA
CEO
Frank H. Laukien
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2024

Revenue of $3.4B through the costs to a net profit of $113.1M · income statement of the 10-K

8% operating margin
Revenue to Gross profit: $1.6BRevenue to Cost of revenue: $1.7BGross profit to Operating profit: $253.1MGross profit to Operating expenses: $1.4BOperating profit to Net profit: $113.1MOperating profit to Tax & other: $140.0MOperating expenses to R&D: $376.5MOperating expenses to Sales, admin & other: $1.0B Revenue: $3.4B REVENUE $3.4B +14% Y/Y Gross profit: $1.6B · 49% margin GROSS PROFIT $1.6B 49% margin · +9% Y/Y Cost of revenue: $1.7B · 51% of revenue COST OF REVENUE $1.7B 51% of revenue Operating profit: $253.1M · 8% margin OPERATING PROFIT $253.1M 8% margin · −42% Y/Y Operating expenses: $1.4B · 41% of revenue OPERATING EXPENSES $1.4B 41% of revenue Net profit: $113.1M · 3% margin NET PROFIT $113.1M 3% margin · −74% Y/Y Tax & other: $140.0M · 4% of revenue TAX & OTHER $140.0M 4% of revenue R&D: $376.5M · 11% of revenue R&D $376.5M 11% of revenue Sales, admin & other: $1.0B · 30% of revenue SALES, ADMIN & OTHER $1.0B 30% of revenue
Gross profit $1.6B 49% margin · +9% Y/Y
Operating profit $253.1M 8% margin · −42% Y/Y
Net profit $113.1M 3% margin · −74% Y/Y
The full income statement, year by year

BRKR among Technology peers

Six ratios from the latest 10-K. Each corner is the share of 230 peers the company is above, not a score.

Compare
Revenue growth: 2.1%, above 14% of 230 peers (their median 13.4%) REVENUE GROWTH 2.1% · above 14% Gross margin: 47.7%, above 30% of 210 peers (their median 61.4%) GROSS MARGIN 47.7% · above 30% Operating margin: -2.0%, above 17% of 222 peers (their median 11.5%) OPERATING MARGIN -2.0% · above 17% Net margin: -3.5%, above 15% of 228 peers (their median 10.4%) NET MARGIN -3.5% · above 15% FCF margin: 7.0%, above 22% of 225 peers (their median 20.0%) FCF MARGIN 7.0% · above 22% Return on capital: -0.6%, above 2% of 160 peers (their median 9.8%) RETURN ON CAPITAL -0.6% · above 2%
BRKR Peer median Below the median

What changed

23 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 27, 2026 against Mar 3, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Interim Goodwill Impairment Test - Bruker Spatial Biology and Automation Reporting Units (“As described in Notes 2 and 6 to the consolidated financial statements, as of December 31, 2025, the goodwill associated with the Bruker Scientific Instruments (BSI) NANO segment was $525.8 million, of which a portion relates to the Bruker Spatial Biology (BSB) reporting unit and the goodwill associ”). No longer listed: Acquisition of ELITechGroup - Valuation of Customer Relationships and Technology. Same as last year: Revenue Recognition - System Sales
  • Receivables -3.6% ($565.5M to $544.9M) vs revenue +2.1% ($3.4B to $3.4B), -5.7 pts apart
9 more checks with nothing to note
  • Cash from operations $134.1M vs net income −$8.6M (FY ending Dec 31, 2025)
  • Inventory +2.5% ($1.1B to $1.1B) vs revenue +2.1% ($3.4B to $3.4B), +0.4 pts apart
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

23 paragraphs in Risk Factors that were not in the 10-K filed Mar 3, 2025. Quoted as filed.

All 23 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    New U.S. and reciprocal tariffs that have been imposed, and remain subject to potential change and other uncertainties, have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so in the foreseeable future. Recently, the U.S. government has indicated its intent to modify…
  2. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future. A significant portion of our revenue is derived from sales into China, some of which are directly funded through Chinese…
  3. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    In addition to the foreign currency exposure associated with differences between where our products are manufactured and sold by us and our competitors, our exposure to currency exchange rate fluctuations results from the currency translation exposure
  4. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    As of December 31, 2025, we had an outstanding aggregate principal amount of debt totaling approximately $1.9 billion and had $900.0 million available for borrowing under the 2024 Revolving Credit Agreement, subject to compliance with financial covenant ratios.

New risk paragraphs, against peers

Latest 10-K of each, Technology companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$2.5B$3.0B$3.4B$3.4B
Net income$296.6M$427.2M$113.1M−$8.6M
Operating cash flow$274.4M$350.1M$251.3M$134.1M
Free cash flow$145.2M$243.2M$136.0M$43.3M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$3.4B ▲ 2.1% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Bruker Corp, Billerica, MA · from the 10-K filed Feb 27, 2026

We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Many of our products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. Our products and solutions address the rapidly evolving needs of a diverse array of customers in life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology.

Headquarters
Billerica, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, Bruker had approximately 11,085 employees worldwide" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Mar 3, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BRKR/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.